- MicuRx attracted a slew of investors including China Merchants Group’s investment bank unit China Merchants Securities, Korea Investment Partners, Yingke PE, Founder Securities’ investment arm Founder H Fund, Zhongtai Ventures, and Detong Capital.
- The fresh proceeds will be used for new drug development, global clinical trials, pipeline advancement and drug commercialisation in China, the company said.
- MicuRx completed its $43-million Series D round in August 2020 led by Huagai Capital with the participation of Sinopharm-CICC and Zero2IPO Asset Management.
DEALSTREETASIA.COM24 Dec, 2020
